HighTower Advisors’s AbbVie ABBV Stock Holding History

HighTower Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361M	Buy	1,658,024 +29,113	+2%	+$6.46M	0.38%	46
2025 Q4	$372M	Sell	1,628,911 -12,873	-0.8%	-$2.93M	0.41%	43
2025 Q3	$380M	Buy	1,641,784 +51,071	+3%	+$10.4M	0.43%	40
2025 Q2	$295M	Buy	1,590,713 +10,356	+0.7%	+$1.92M	0.37%	50
2025 Q1	$331M	Buy	1,580,357 +6,528	+0.4%	+$1.27M	0.45%	41
2024 Q4	$280M	Buy	1,573,829 +100,318	+7%	+$18.4M	0.38%	47
2024 Q3	$291M	Buy	1,473,511 +38,310	+3%	+$7.15M	0.42%	42
2024 Q2	$246M	Sell	1,435,201 -26,437	-2%	-$4.38M	0.38%	43
2024 Q1	$266M	Sell	1,461,638 -76,699	-5%	-$13.2M	0.43%	43
2023 Q4	$238M	Sell	1,538,337 -2,567	-0.2%	-$374K	0.4%	42
2023 Q3	$230M	Buy	1,540,904 +222,183	+17%	+$32.6M	0.43%	42
2023 Q2	$178M	Sell	1,318,721 -7,573	-0.6%	-$1.11M	0.35%	53
2023 Q1	$212M	Sell	1,326,294 -47,670	-3%	-$7.29M	0.46%	35
2022 Q4	$222M	Buy	1,373,964 +70,736	+5%	+$10.8M	0.51%	29
2022 Q3	$175M	Buy	1,303,228 +723	+0.1%	+$104K	0.47%	34
2022 Q2	$200M	Sell	1,302,505 -55,552	-4%	-$8.49M	0.52%	28
2022 Q1	$220M	Sell	1,358,057 -674	-0%	-$97.9K	0.49%	30
2021 Q4	$184M	Buy	1,358,731 +64,825	+5%	+$7.66M	0.4%	46
2021 Q3	$139M	Buy	1,293,906 +25,174	+2%	+$2.88M	0.37%	50
2021 Q2	$143M	Buy	1,268,732 +137,563	+12%	+$15.5M	0.41%	42
2021 Q1	$122M	Buy	1,131,169 +23,176	+2%	+$2.48M	0.39%	51
2020 Q4	$119M	Buy	1,107,993 +93,570	+9%	+$8.99M	0.49%	34
2020 Q3	$89M	Buy	1,014,423 +97,443	+11%	+$9.17M	0.43%	45
2020 Q2	$90.1M	Buy	916,980 +82,921	+10%	+$7.3M	0.49%	39
2020 Q1	$63.6M	Buy	834,059 +102,902	+14%	+$8.76M	0.41%	48
2019 Q4	$64.8M	Sell	731,157 -24,901	-3%	-$2.07M	0.38%	53
2019 Q3	$57.3M	Buy	756,058 +29,523	+4%	+$2.02M	0.31%	64
2019 Q2	$52.8M	Buy	726,535 +157,369	+28%	+$12.4M	0.31%	68
2019 Q1	$45.8M	Buy	569,166 +769	+0.1%	+$62.9K	0.31%	64
2018 Q4	$52.4M	Buy	568,397 +44,010	+8%	+$3.87M	0.4%	45
2018 Q3	$49.6M	Buy	524,387 +31,479	+6%	+$2.99M	0.36%	54
2018 Q2	$45.7M	Buy	492,908 +19,046	+4%	+$1.86M	0.36%	52
2018 Q1	$44.9M	Buy	473,862 +33,779	+8%	+$3.71M	0.38%	46
2017 Q4	$42.6M	Sell	440,083 -122,441	-22%	-$11.5M	0.35%	52
2017 Q3	$50M	Sell	562,524 -23,313	-4%	-$1.77M	0.43%	41
2017 Q2	$42.5M	Buy	585,837 +95,774	+20%	+$6.44M	0.38%	47
2017 Q1	$32M	Buy	490,063 +9,780	+2%	+$615K	0.31%	67
2016 Q4	$30.1M	Sell	480,283 -164,088	-25%	-$10M	0.33%	60
2016 Q3	$40.6M	Buy	644,371 +16,679	+3%	+$1.08M	0.47%	37
2016 Q2	$38.8M	Sell	627,692 -38,250	-6%	-$2.33M	0.49%	33
2016 Q1	$38M	Buy	665,942 +21,868	+3%	+$1.22M	0.12%	53
2015 Q4	$38.2M	Buy	644,074 +2,326	+0.4%	+$134K	0.45%	40
2015 Q3	$34.9M	Buy	641,748 +92,698	+17%	+$6.03M	0.46%	36
2015 Q2	$36.9M	Buy	549,050 +40,525	+8%	+$2.65M	0.59%	28
2015 Q1	$29.8M	Buy	508,525 +37,577	+8%	+$2.27M	0.44%	42
2014 Q4	$30.8M	Buy	470,948 +61,416	+15%	+$3.87M	0.47%	36
2014 Q3	$23.7M	Buy	409,532 +81,054	+25%	+$4.5M	0.4%	42
2014 Q2	$18.5M	Buy	328,478 +112,503	+52%	+$5.9M	0.32%	60
2014 Q1	$11.1M	Buy	215,975 +11,417	+6%	+$577K	0.22%	103
2013 Q4	$10.8M	Sell	204,558 -23,092	-10%	-$1.13M	0.22%	104
2013 Q3	$10.2M	Buy	227,650 +12,560	+6%	+$557K	0.25%	87
2013 Q2	$8.89M	Buy	+215,090	New	+$9.41M	0.24%	90

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's ABBV Position: Q1 2026 in Review

HighTower Advisors increased its AbbVie (ABBV) stake by 1.8% in Q1 2026, buying an estimated $6.46M and bringing the position to 1,658,024 shares worth $361M. The position accounts for 0.38% of the portfolio, ranked #46.

HighTower Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $380M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

HighTower Advisors held 1,658,024 shares of AbbVie worth $361M as of Q1 2026.
HighTower Advisors bought 29,113 AbbVie shares in Q1 2026, an estimated $6.46M.
AbbVie made up 0.38% of HighTower Advisors's portfolio in Q1 2026, its #46 holding.
HighTower Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
HighTower Advisors's AbbVie position peaked at $380M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.